Bolt Biotherapeutics Announces First Patient Dosed in Phase I/II Study of BDC-3042 in Patients with Advanced Cancers

Bolt Biotherapeutics announced that the first patient has been dosed with BDC-3042 in the single-agent dose-escalation portion of this first-in-human Phase I/II clinical study. They evaluate BDC-3042 in patients with metastatic or unresectable cancers including triple-negative breast cancer, colorectal cancer, non-small cell lung cancer.